On June 4, Insilico Medicine fell 5.21% in regular trading, trading at HK$38.66/share, with trading volume of HK$22.72 million. The stock has extended its recent downtrend, with cumulative losses approaching 40% over the past month.

On the news front, the company previously issued a voluntary announcement on May 27 clarifying that it currently has no definitive plan for a secondary listing in Abu Dhabi. The market had earlier anticipated this move would help expand international financing channels and deepen its Middle East strategic presence, and the dashed expectations continue to weigh on sentiment.

More critically, having listed on the Hong Kong Stock Exchange in December last year, the company has now formally entered its lock-up expiry window. Shares held by certain cornerstone investors and employee equity incentive plans are approaching their release dates, intensifying market concerns over potential selling pressure. Additionally, the Life Sciences Tools and Services sector showed broad weakness today, with WUXI BIO down 0.55%, WUXI APPTEC down 0.95%, GenScript Bio down 2.76%, and XTALPI down 1.03%, further dragging on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)